Progress towards stem cell treatment for Parkinson’s Date 15 April 2025 Two separate research studies have both shown promising early results for a treatment that aims to replace brain cells that are lost in Parkinson’s.
Exploring new drugs to boost energy in brain cells Date 3 April 2025 We’ve awarded Pretzel Therapeutics £200,000 to investigate a new drug which could prevent cells from dying in Parkinson’s.
Over £435,000 awarded to new research exploring ways to manage Parkinson’s symptoms Date 2 April 2025 In our latest round of grants we’ve awarded funding for new projects that aim to improve symptoms of Parkinson’s without the need for extra medication.
Phase 3 trial of ambroxol is underway Date 1 April 2025 The first participant has received either ambroxol or the placebo in the ASPro-PD trial. This marks the start of 330 people with Parkinson’s taking a component of an already approved drug over 2 years to see if it is beneficial.
New centre to accelerate Parkinson’s research Date 7 March 2025 Parkinson’s UK and the UK Dementia Research Institute (UK DRI) join forces to establish a pioneering research centre.
Global cases of Parkinson’s predicted to rise to 25 million by 2050 Date 5 March 2025 A study predicting health trends worldwide suggests that incidence of Parkinson’s is rising due to an ageing population.
Future leaders in research recognised with Parkinson’s UK funding award Date 11 February 2025 Nearly £600,000 has been awarded to 2 outstanding scientists to develop their Parkinson’s research careers.
Results from the phase 3 trial of exenatide published Date 4 February 2025 The full results show that exenatide had no benefits over the placebo and didn’t slow the progression of Parkinson’s.
Adaptive deep brain stimulation in the news Date 29 January 2025 Adaptive deep brain stimulation in the news
Blood pressure drug shows promise for reducing tremor in Parkinson’s Date 9 January 2025 A small study of a drug called propranolol looked effective in easing tremor both at rest and in stressful situations for people with Parkinson’s.